Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Author
Kolinsky, M. P.
Roubaud, G.
ÖZGÜROĞLU, Mustafa
Penel, N.
Matsubara, N.
Mehra, N.
Procopio, G.
Feyerabend, S.
Joung, J. Y.
Gravis, G.
Nishimura, K.
Gedye, C.
Padua, C.
Shore, N.
Thiery-Vuillemin, A.
Gresty, C.
Brickel, N.
Burgents, J.
Allen, A.
Fizazi, K.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/3575
https://doi.org/10.1016/j.annonc.2020.08.883
Collections